{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:48:43Z","timestamp":1787759323194,"version":"build-2784847793"},"reference-count":28,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"\n Background:<\/jats:title>\n There are limited oral treatment options available for resistant Gram-negative bacterial (GNB) infections. Minocycline, a second-generation tetracycline antibiotic, offers good bioavailability and broad-spectrum coverage that may be an option for GNB infections.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n We conducted a retrospective review of minocycline susceptibility testing performed on GNB isolates at the Mayo Clinic reference lab between 2013 and 2022. Minocycline susceptibility was evaluated with a focus on difficult-to-treat organisms and relevant anatomic source. Organisms included resistant isolates of\n Escherichia coli<\/jats:italic>\n and\n Klebsiella pneumoniae<\/jats:italic>\n ; high-risk ampC-derepressors, including\n Citrobacter freundii, Enterobacter cloacae,<\/jats:italic>\n and\n K. aerogenes;<\/jats:italic>\n and clinically challenging non-Enterobacterales,\n Acinetobacter species, Achromobacter species,<\/jats:italic>\n and\n Stenotrophomonas maltophilia<\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Of 217,206 GNB isolates, 18,148 Enterobacterales (EB) and 8,190 non-\n Enterobacter<\/jats:italic>\n isolates were tested for minocycline susceptibility. Of these, 80% of all EB and 92% of non-EB isolates were susceptible. Among\n E. coli<\/jats:italic>\n isolates with ceftriaxone, ciprofloxacin, meropenem, or multidrug resistance, minocycline susceptibility was 78%, 76%, 70%, and 70.9%, respectively. Among the\n K. pneumoniae<\/jats:italic>\n isolates with ceftriaxone, ciprofloxacin, meropenem, or multidrug resistance, minocycline susceptibility was 46%, 38%, 37%, and 39.3%, respectively. 85% of\n C. freundii<\/jats:italic>\n , 81% of\n E. cloacae,<\/jats:italic>\n and 85% of\n K. aerogenes<\/jats:italic>\n isolates were susceptible to Minocycline. 83.5% of\n Achromobacter<\/jats:italic>\n species isolates, 66% of\n Acinetobacter<\/jats:italic>\n species isolates, and 99.1% of\n S. maltophilia<\/jats:italic>\n isolates were susceptible.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n \n Our study reports the largest collection of minocycline susceptibility findings in GNB. Minocycline showed\n in vitro<\/jats:italic>\n activity against many difficult-to-treat GNB isolates, including ceftriaxone- and multidrug-resistant\n E. coli<\/jats:italic>\n and some\n K. pneumoniae<\/jats:italic>\n isolates, common Amp-C-producing species, and non-fermenting GNB, including\n Stenotrophomonas<\/jats:italic>\n ,\n Acinetobacter<\/jats:italic>\n , and\n Achromobacter<\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10766294261424485","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:45:56Z","timestamp":1774964756000},"page":"128-134","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Show Me the \u201cMino:\u201d\n In Vitro<\/i>\n Efficacy of Minocycline on Clinical Gram-Negative Bacterial Isolates"],"prefix":"10.1177","volume":"32","author":[{"given":"Patrick D.","family":"Crowley","sequence":"first","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nischal","family":"Ranganath","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA."},{"name":"Division of Hospital Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Portia","family":"Mira","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Streck","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Challener","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina G.","family":"Rivera","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abu Saleh","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"e_1_3_2_2_2","first-page":"2669","volume-title":"Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases","author":"Nelson GE","year":"2020","unstructured":"Nelson GE, , Greene, , Matthew H. Enterobacteriaceae. In: Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020. pp. 2669\u20132685.","edition":"9"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127007101100504"},{"key":"e_1_3_2_5_2","volume-title":"Minocycline: Drug Information","author":"Merative Micromedex","year":"2025","unstructured":"Merative Micromedex. (2025). Minocycline: Drug Information. IBM Micromedex. [January 11, 2025]."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000975"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.7150\/jbji.17353"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis966"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(86)90321-3"},{"key":"e_1_3_2_10_2","volume-title":"CLSI standard M07","author":"CLSI","year":"2024","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 12th ed. CLSI standard M07. Clinical and Laboratory Standards Institute: Wayne, PA; 2024.","edition":"12"},{"key":"e_1_3_2_11_2","volume-title":"CLSI supplement M100","author":"CLSI","year":"2024","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 34thed. CLSI supplement M100. Clinical and Laboratory Standards Institute; 2024.","edition":"34"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01452-22"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01809-20"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12020322"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2013.03.001"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-019-01291-9"},{"key":"e_1_3_2_17_2","unstructured":"Microsoft Corporation. (2018. Microsoft Excel. Available from: https:\/\/office.microsoft.com\/excel"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12563"},{"issue":"6","key":"e_1_3_2_19_2","first-page":"487","article-title":"Infectious complications of advanced cancer","volume":"8","author":"Homsi J","year":"2000","unstructured":"Homsi J, , Walsh D, , Panta R, , Lagman R, , Nelson KA, , Longworth DL. Infectious complications of advanced cancer. Support Care Cancer, 2000 Nov;8(6):487\u2013492.","journal-title":"Support Care Cancer"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41393-023-00899-x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197509040-00005"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir112"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464010-00005"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.3.1.46"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.144"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00111-13"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932050-00001"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-024-05073-0"},{"key":"e_1_3_2_29_2","first-page":"318","volume-title":"Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases","author":"Moffa M","year":"2020","unstructured":"Moffa M, , Brook I. Tetracyclines, Glycylcyclines, and Chloramphenicol. In: Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020. pp. 318\u2013336.","edition":"9"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10766294261424485","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10766294261424485","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10766294261424485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:17:26Z","timestamp":1783599446000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10766294261424485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"alternative-id":["10.1177\/10766294261424485"],"URL":"https:\/\/doi.org\/10.1177\/10766294261424485","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}